Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13356071 | 0.92 | KDM4E (0.50) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| Hydrochloric Acid SCHEMBL3248771 | 0.91 | KDM4E (0.49) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL5113391 | 0.89 | TSHR (0.58) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL13873445 | 0.85 | KDM4E (0.50) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL30617721 | 0.85 | KDM4E (0.50) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL17323592 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL17703585 | 0.84 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL17323608 | 0.82 | RAB9A (0.44) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL20734831 | 0.82 | SMN1; SMN2 (0.57) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL23639562 | 0.81 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1CYP1A2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-28 | — | — | US | disclosed |
| WO-2019032640-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/MTOR AND MEK/PI3K/MTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | MTOR, JAK2, JAK1 | ALDH1A1 4608/4885KDM4E 1270/4885MEN1 1172/4885 |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | MTOR, JAK2, JAK1 | ALDH1A1 4608/4885KDM4E 1270/4885MEN1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.